In this review paper, the most recent research on intracerebral hemorrhage (ICH) is summarized and novelperspectives are offered on the pathomechanisms of ICH. These underlying pathomechanisms of ICH provide clues for development of novel drugs or drug target screening. Specifically, recent research has provided evidence that iron chelators, lipid peroxidation/ferroptosis inhibitors, agonists or antagonists of prostaglandin E2 receptors (EP1/3 or EP2), and nonsteroidal anti-inflammatory drugs protect against ICH-induced brain edema, secondary brain tissue damage as well as inhibition of the toxicity in related tissue damage products. This review will provide a theoretical basis for testing new compounds that may have potential for future clinical trials.